{"id":"https://openalex.org/W4297769733","doi":"https://doi.org/10.1016/s0090-8258(22)01258-6","title":"OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039)","display_name":"OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039)","publication_year":2022,"publication_date":"2022-08-01","ids":{"openalex":"https://openalex.org/W4297769733","doi":"https://doi.org/10.1016/s0090-8258(22)01258-6"},"language":"en","primary_location":{"id":"doi:10.1016/s0090-8258(22)01258-6","doi":"https://doi.org/10.1016/s0090-8258(22)01258-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0090-8258(22)01258-6","pdf_url":null,"source":{"id":"https://openalex.org/S2574783","display_name":"Gynecologic Oncology","issn_l":"0090-8258","issn":["0090-8258","1095-6859"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gynecologic Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000135223","display_name":"Melissa M. Hardesty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112774","display_name":"Alaska Women's Cancer Care","ror":"https://ror.org/01m5a8633","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210112774"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Hardesty","raw_affiliation_strings":["Alaska Women\u2019s Cancer Care, Anchorage, AK, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alaska Women\u2019s Cancer Care, Anchorage, AK, United States","institution_ids":["https://openalex.org/I4210112774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002154444","display_name":"Thomas C. Krivak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799629232","display_name":"Western Pennsylvania Hospital","ror":"https://ror.org/02yhx1447","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799629232"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Krivak","raw_affiliation_strings":["The Western Pennsylvania Hospital, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Western Pennsylvania Hospital, Pittsburgh, PA","institution_ids":["https://openalex.org/I2799629232"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016843577","display_name":"Gail Shaw Wright","orcid":"https://orcid.org/0000-0002-3795-7573","observed_orcids":["https://orcid.org/0000-0002-3795-7573"]},"institutions":[{"id":"https://openalex.org/I4210118420","display_name":"Florida Cancer Specialists & Research Institute","ror":"https://ror.org/02px37122","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210118420"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gail Wright","raw_affiliation_strings":["Florida Cancer Specialists and Research Institute, Trinity, FL, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists and Research Institute, Trinity, FL, United States","institution_ids":["https://openalex.org/I4210118420"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003060935","display_name":"Erika Paige Hamilton","orcid":"https://orcid.org/0000-0002-1911-0336","observed_orcids":["https://orcid.org/0000-0002-1911-0336"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika Hamilton","raw_affiliation_strings":["Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, United States","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037841210","display_name":"Evelyn L. Fleming","orcid":"https://orcid.org/0000-0002-0490-3683","observed_orcids":["https://orcid.org/0000-0002-0490-3683"]},"institutions":[{"id":"https://openalex.org/I1289422878","display_name":"Dartmouth\u2013Hitchcock Medical Center","ror":"https://ror.org/00d1dhh09","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I107672454","https://openalex.org/I1289422878","https://openalex.org/I4390039337"]},{"id":"https://openalex.org/I4390039367","display_name":"Dartmouth Cancer Center","ror":"https://ror.org/044b05b34","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039367"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Evelyn Fleming","raw_affiliation_strings":["Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States","institution_ids":["https://openalex.org/I1289422878","https://openalex.org/I4390039367"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078713088","display_name":"Jimmy Belotte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jimmy Belotte","raw_affiliation_strings":["GlaxoSmithKline, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Waltham, MA, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035533581","display_name":"Erika Krasnickas Keeton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika Keeton","raw_affiliation_strings":["GlaxoSmithKline, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Waltham, MA, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ping Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ping Wang","raw_affiliation_strings":["GlaxoSmithKline, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Waltham, MA, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022416463","display_name":"Aine Clements","orcid":"https://orcid.org/0000-0002-7807-8786","observed_orcids":["https://orcid.org/0000-0002-7807-8786"]},"institutions":[{"id":"https://openalex.org/I2799782091","display_name":"Riverside Methodist Hospital","ror":"https://ror.org/02hsexy86","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I127073530","https://openalex.org/I2799782091"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aine Clements","raw_affiliation_strings":["Riverside Methodist Hospital, Columbus, OH, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Riverside Methodist Hospital, Columbus, OH, United States","institution_ids":["https://openalex.org/I2799782091"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059468772","display_name":"Heidi J. Gray","orcid":"https://orcid.org/0000-0002-3927-6739","observed_orcids":["https://orcid.org/0000-0002-3927-6739"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heidi Gray","raw_affiliation_strings":["University of Washington, Seattle, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington, Seattle, WA, United States","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062837404","display_name":"Gottfried E. Konecny","orcid":"https://orcid.org/0000-0001-6083-657X","observed_orcids":["https://orcid.org/0000-0001-6083-657X"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gottfried Konecny","raw_affiliation_strings":["University of California Los Angeles, Los Angeles, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California Los Angeles, Los Angeles, CA, United States","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052236281","display_name":"Richard G. Moore","orcid":"https://orcid.org/0000-0001-5598-5263","observed_orcids":["https://orcid.org/0000-0001-5598-5263"]},"institutions":[{"id":"https://openalex.org/I28792581","display_name":"University of Rochester Medicine","ror":"https://ror.org/00trqv719","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I28792581","https://openalex.org/I5388228"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Moore","raw_affiliation_strings":["Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States","institution_ids":["https://openalex.org/I28792581"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091030588","display_name":"Debra L. Richardson","orcid":"https://orcid.org/0000-0002-3992-8610","observed_orcids":["https://orcid.org/0000-0002-3992-8610"]},"institutions":[{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debra Richardson","raw_affiliation_strings":["University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States","institution_ids":["https://openalex.org/I49332381"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4020,"currency":"USD","value_usd":4020},"apc_paid":null,"fwci":0.1045,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.41614016,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"166","issue":null,"first_page":"S27","last_page":"S28"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/niraparib","display_name":"niraparib","score":0.9869999885559082},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/advanced-ovarian-cancer","display_name":"advanced ovarian cancer","score":0.921999990940094},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.6179999709129333},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.9049999713897705},{"id":"https://openalex.org/keywords/platinum-sensitive-recurrent-ovarian-cancer","display_name":"platinum-sensitive recurrent ovarian cancer","score":0.7599999904632568},{"id":"https://openalex.org/keywords/high-grade-serous-ovarian-carcinoma","display_name":"high-grade serous ovarian cancer","score":0.8989999890327454},{"id":"https://openalex.org/keywords/endometrioid-ovarian-carcinoma","display_name":"endometrioid ovarian cancer","score":0.996999979019165},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7789999842643738},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8429999947547913},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.8190000057220459},{"id":"https://openalex.org/keywords/homologous-recombination-deficiency","display_name":"homologous recombination deficiency","score":0.7789999842643738},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.527999997138977},{"id":"https://openalex.org/keywords/tumor-hypoxia","display_name":"tumor hypoxia","score":0.6179999709129333}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8815746307373047},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8471218347549438},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6544831395149231},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.618183434009552},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6144014596939087},{"id":"https://openalex.org/C2781100745","wikidata":"https://www.wikidata.org/wiki/Q1977435","display_name":"Debulking","level":4,"score":0.5306994318962097},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5303885340690613},{"id":"https://openalex.org/C2780194787","wikidata":"https://www.wikidata.org/wiki/Q4836333","display_name":"BRCA mutation","level":4,"score":0.5206210613250732},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5012125968933105},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.45199090242385864},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3434615135192871},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.27584999799728394},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.23655912280082703}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s0090-8258(22)01258-6","doi":"https://doi.org/10.1016/s0090-8258(22)01258-6","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0090-8258(22)01258-6","pdf_url":null,"source":{"id":"https://openalex.org/S2574783","display_name":"Gynecologic Oncology","issn_l":"0090-8258","issn":["0090-8258","1095-6859"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gynecologic Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.8199999928474426,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3015710395","https://openalex.org/W2897751981","https://openalex.org/W4281698295","https://openalex.org/W4388494884","https://openalex.org/W4411858265","https://openalex.org/W4388496268","https://openalex.org/W4414649593","https://openalex.org/W2890888307","https://openalex.org/W4388452770","https://openalex.org/W4312982978"],"abstract_inverted_index":null,"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-10-01T00:00:00"}